DHX58 and cancer: Nevertheless, RLRs inhibition holds promise for the treatment of autoimmune diseases and interferonopathies, while RLR agonists may have a future in cancer therapy, to induce a pre-senescence state or to increase sensitivity to apoptotic agents.